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Accepted 12 September 2011; Published online 23 December 2011AbstractObjective: To enable multicriteria benefiterisk (BR) assessment of any number of alternative treatments using all available evidence
from a network of clinical trials.
Study Design and Setting: We design a general method for multicriteria decision aiding with criteria measurements from Mixed Treat-
ment Comparison (MTC) analyses. To evaluate the method, we apply it to BR assessment of four second-generation antidepressants and
placebo in the setting of a published peer-reviewed systematic review.
Results: The analysis without preference information shows that placebo is supported by a wide range of possible preferences. Pref-
erence information provided by a clinical expert showed that although treatment with antidepressants is warranted for severely depressed
patients, for mildly depressed patients placebo is likely to be the best option. It is difficult to choose between the four antidepressants, and
the results of the model indicate a high degree of uncertainty.
Conclusions: The designed method enables quantitative BR analysis of alternative treatments using all available evidence from a net-
work of clinical trials. The preference-free analysis can be useful in presenting the results of an MTC considering multiple out-
comes.
 2012 Elsevier Inc.
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Open access under the Elsevier OA license.1. Introduction
The pharmaceutical regulatory authorities and pharma-
ceutical health care decision makers (DMs) increasingly
request an explicit benefiterisk (BR) analysis of drugs be-
cause it can provide a basis for rational decisions when
choosing a particular therapy [1]. Drug BR analysis can
be used to identify trade-offs between benefit and risk,
where benefit is the efficacy of a drug and risk relates to
its safety [2]. If there is only one measure of efficacy and
one measure of safety, the BR analysis can be conducted by
plotting the joint density of the benefit and risk criteria on
a plane [3]. However, there is a growing need for evidence-
based pharmacotherapy to consider more than two criteria,
such as multiple safety criteria, the patient’s quality of life,
and costs. In these cases, the two-dimensional visualization
technique cannot be applied.* Corresponding author. Tel.: þ31-50-361-4522.
E-mail address: g.h.m.van.valkenhoef@rug.nl (G. van Valkenhoef).
0895-4356 2012 Elsevier Inc.
doi: 10.1016/j.jclinepi.2011.09.005
Open access under the Elsevier OA license.Multicriteria decision aiding methods can help by struc-
turing the decision problem and making the underlying
value trade-offs explicit. Specifically, Tervonen et al. [4]
proposed a stochastic multicriteria acceptability analysis
(SMAA) model for analyzing BR. Their model allows tak-
ing into account the probability distributions of the criteria
measurements and is able to quantify the uncertainty sur-
rounding a decision. Moreover, measurements and value
judgments (preferences) are clearly separated. However,
the model relies on a single trial to evaluate the compara-
tive BR profiles of the alternatives. In most cases, a BR as-
sessment will need to be based on evidence synthesized
from multiple trials or possibly a complex network of trials.
Although evidence synthesis is most often done through
pairwise meta-analyses, they are ill suited as a basis for
a computational BR method for a number of reasons. First,
relative effects have to be assessed against a common com-
parator, and not all evidence structures have a single treat-
ment against which all others are compared [5]. Second,
choosing a common comparator introduces a selection bias
by excluding studies that do not include the comparator.
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Key finding:
 Network meta-analysis can be combined with mul-
ticriteria decision aiding to perform benefiterisk
analysis comparing multiple treatments.
What this adds to what was known?
 The new method enables comprehensive quantita-
tive benefiterisk analysis based on a network of
trials.
 The case study provides additional insight into the
results of an existing systematic review.
What is the implication, what should change now?
 Trade-offs considered in benefiterisk analyses can
be made more explicit.
 The method can be used to present network meta-
analysis results with multiple outcomes.Sensitivity analyses would have to be carried out for
every possible choice of comparator, and even then some
studies might be excluded. Finally, when a large number
of treatments are available, most evidence may be indirect
regardless of the chosen common comparator. Traditional
meta-analysis does not allow these indirect comparisons
to be taken into account.
The recently proposed Mixed Treatment Comparison
(MTC) method (also known as network meta-analysis) syn-
thesizes all the available evidence through application of
a Bayesian evidence network [6,7]. The relative effects of
all included treatments are estimated using both direct
and indirect evidence. In this way, the results are consistent
regardless of the chosen comparator, and it is not necessary
that one of the treatments has been compared with all
others. Graphical summaries of MTC results have been pro-
posed as an informal decision aid in trading effectiveness
against other factors [8]. To enable the formal BR analysis
of a number of alternative treatments taking into account all
relevant studies, this article proposes to apply MTC for ev-
idence synthesis in SMAA-based multicriteria drug BR
analysis. We call this method MTC/SMAA, and for illustra-
tion, we constructed a model to evaluate the comparative
BR profiles of four second-generation antidepressants and
placebo using 25 studies from the literature, selected on
the basis of an existing systematic review [9].2. Stochastic multicriteria acceptability analysis
SMAA-2 [10] considers a discrete multicriteria deci-
sion problem consisting of a set of m alternatives thatare evaluated in terms of n criteria. The vector of criteria
measurements corresponding to alternative i is denoted
by xi5ðxi1;.; xinÞ, where xik is a random variable repre-
senting the performance of alternative i on criterion k,
modeled using some density function. For each criterion,
a partial value function vkðxikÞ is defined to normalize the
criteria measurements so that they are represented by
values between 0 (the worst value) and 1 (the best
value). The overall value function is then defined as
a weighted additive combination of the partial value
functions:v

xi;w

5
Xn
k51
wk$vk

xik

;where vðxi;wÞOvðxj;wÞ implies that alternative i is pre-
ferred to alternative j given the weight vector w. The
weights define relative importances of the scale swings
(changes from the worst to the best criterion values), and
wkO wl implies that if the DM would have to choose be-
tween improving either criterion k or criterion l from the
worst to the best value, he or she would increase the perfor-
mance on criterion k.
The DM’s preferences may be unknown or partially
known, and therefore the weights w are also represented
by a probability density. Total lack of preference informa-
tion is represented by a uniform distribution in the feasible
weight space. Partial information, such as importance rank-
ing of the criteria, can easily be included by restricting the
feasible weight space accordingly [10].
For given (exact) values of x and w, the rank of each
alternative is defined as an integer from the best rank
(51) to the worst rank (5m) by means of a ranking func-
tion rank(i, x, w). The main decision aiding measure is
the rank acceptability index, denoted by bri . It describes
the share of all possible values of the weight vector w
and criteria measurements x for which rank(i, x, w)5 r.
For example, b52 5 0:3 means alternative 2 has fifth rank
acceptability 0.3. The preferred (best) alternatives are those
with high acceptabilities for the best ranks.
In addition to using the value function to rank the alter-
natives for an elicited weight vector w, the SMAA methods
allow computing the weight vector a ‘‘typical’’ DM sup-
porting each alternative might have. This so-called central
weight vector wci can be presented to the DM to help him or
her understand what kind of weights would favor a certain
alternative i. The confidence factor pci is the probability for
alternative i to obtain the first rank when its central weight
vector is chosen. The confidence factors indicate whether
the criteria measurements are sufficiently accurate to
discern the efficient alternatives. Low confidence factors
(!0.50) should be interpreted with care, as then even if
a DM finds the central weight vector corresponding to his
or her preferences, there might be another alternative that
achieves a higher first rank acceptability with those
weights.
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The MTC method (also called network meta-analysis)
synthesizes all available clinical evidence through applica-
tion of a Bayesian hierarchical model [6,7]. It enables the
detection of heterogeneity (differences in studies compar-
ing the same treatments) and inconsistency (differences be-
tween direct and indirect comparisons) in the evidence
[6,11,12]. In this section, we briefly introduce the structure
of a random effects MTC model for dichotomous data be-
cause this type of model will be used in the case study (Sec-
tion 5). For other model types and the handling of multiarm
trials, we refer to the studies by Salanti et al. [6] and Lu and
Ades [11].
Let i be a clinical trial. For each included treatment x,
we are given the sample size ni,x and the number of events
ri,x, modeled as a binomial process:ri;x | Bin

pi;x;ni;x

;where pi,x is the success probability (i.e., the absolute risk
of an event). The risk pi,x of an effect observed in the indi-
vidual studies is transformed to log odds qi,x throughq5 logitðpÞ5 log

p
1 p

:The inverse transformation is given byp5 logit1ðqÞ5 1
1þ eq:The advantage of this transformation, also used in logis-
tic regression, is that qi,x can be assumed to be normally
distributed. Moreover, if qi,x and qi,y are the log odds for
x and y, then qi,xqi,y is the log odds ratio of y compared
with x in trial i (and eqi;yqi;x is the odds ratio).
Synthesis in MTC models is done in terms of treatment
contrasts (relative effects) and not the absolute effects be-
cause this leads to a more robust model that preserves the
randomization in the trials [7]. To do this, we choose a base-
line treatment b(i) for every trial i, and express the effect of
b(i) asqi;bðiÞ5 logitðpi;bðiÞÞ5mi;
and for every other treatment ysbðiÞ the effect isqi;y5 logitðpi;yÞ5miþ di;bðiÞ;y;
where di,b(i),y is the random effect of y relative to b(i) in
trial i. The random effects are related to the relative effect
as follows:di;x;y | N

dx;y;s
2
x;y

;where dx,y is the relative effect of y compared with x, the
parameter of interest, and s2x;y is the random effects vari-
ance. If we set s2x;y to be identical for all x and y,
s2x;y5s
2, the model is a homogeneous variance model. Oth-
erwise it is a heterogeneous variance model.The model discussed so far is just a Bayesian formula-
tion of pairwise random effects meta-analysis. MTC en-
ables the simultaneous synthesis of a network of trials
through the additional assumption of consistency. Suppose
we have three treatments, say A, B, and C, and studies com-
paring AB, AC, and BC. The consistency assumption then
defines the relation between the relative treatment effects asdAC5dAB þ dBC:
A model that includes this assumption between all rela-
tive effects is a consistency model. Conclusions based on an
MTC model are always derived using the consistency
model. The model is estimated through stochastic simula-
tion, for example, using the BUGS [13] or JAGS [14] soft-
ware. This enables the derivation of a point estimate and
95% credibility interval (CrI, the Bayesian analog to a con-
fidence interval) for each of the relative effects, as well as
the derivation of any other statistics of interest.
The assumption of consistency may be violated by the
data at hand, in which case there exists inconsistency. As
with pairwise meta-analyses, the first step in dealing with
inconsistency should be assessing whether the included
studies are sufficiently similar to be combined. Statistical
means of detecting inconsistency provide an additional
safeguard against drawing conclusions from inconsistent
data sets, although the lack of demonstrable inconsistency
does not prove that the results are free of bias and
diversity.
There are two competing methods for detecting incon-
sistency: inconsistency models [11] and node-splitting
models [12]. Inconsistency models assess inconsistency
by adding inconsistency factors to closed loops in the evi-
dence graph, whereas in node-splitting models a single
comparison is chosen for which the direct evidence and in-
direct evidence are contrasted. Inconsistency models have
the advantage that only a single model needs to be run,
but the results are often difficult to interpret. Node-
splitting models are easier to interpret but require a different
model to be run for each of the potentially inconsistent
comparisons. Which method should be preferred is not
yet clear and, in this article, we will present the results of
the node-splitting analysis because they are easier to inter-
pret and verify them with an inconsistency model.
Inconsistency within an evidence network could reflect
genuine diversity, bias, or a combination of both [6]. If
there is inconsistency, the reason for the inconsistency must
be determined, and a clinically sound explanation must be
given. If the explanation is sufficient, the offending studies
are removed [11], a new inconsistency model is con-
structed, and inconsistency evaluation is repeated until no
relevant inconsistency remains. If there is considerable in-
consistency that cannot be eliminated, the consistency
model cannot be used. It is difficult to judge whether a cer-
tain amount of inconsistency should be considered relevant,
and the debate on how to do this is ongoing [6,11,12].
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The process of performing an MTC/SMAA analysis is
shown in Fig. 1. Analyzing BR based on clinical studies
starts with a systematic review of the available studies rel-
evant to the clinical domain for which BR should be as-
sessed. In this step, which should be carried out with
experts in the clinical domain, the relevant studies, and im-
portant issues are identified. In the ideal case, a relevant
high-quality systematic review can be found in the litera-
ture. Based on the review, the criteria to be considered
are agreed on and operationalized. Then, for each criterion,
the relevant outcomes are extracted from the individual
studies, and inconsistency is evaluated. If there is no rele-
vant inconsistency, a consistency model is subsequently
constructed and used to create the measurements for the
SMAA model. If no reasonable explanation of inconsis-
tency is found, the whole process has to be terminated.choose criteria
run incons. model
investigate
run cons. model
construct SMAA model
k  :=  1
[cons.]
[incons.]
[inconsistency explained]
[unexplained]estimate baseline
identify or perform
systematic review
[all criteria done (k = n)]
select criterion kk := k  + 1
[k  <  n ]
Fig. 1. The process of performing an MTC/SMAA analysis (UML activ-
ity diagram notation). n is the number of criteria. MTC, Mixed Treat-
ment Comparison; SMAA, stochastic multicriteria acceptability
analysis; UML, Unified Modeling Language.4.1. Measurement scales
For reasons of statistical robustness, evidence synthesis
methods estimate only relative effects, whereas absolute
measures are more suitable for applying evidence to con-
crete decisions [15]. In a multicriteria model, the use of ab-
solute measures is desirable because explicit trade-offs
must be made between unit increases in the scaled criteria.
The problem is especially salient for dichotomous criteria
because the result in these cases is expressed as an odds ra-
tio, which is difficult to interpret when assessing the rela-
tive importance of the scale swings between criteria. To
solve this, the log odds ratio can be converted to (absolute)
risk by assuming a distribution for the log odds of a baseline
treatment 1:q1|N

m;s2

:Note that q1 is an overall estimate for treatment 1 and
should not be confused with the trial-level log odds qi,1.
It does not matter which of the m included treatments is se-
lected as the baseline. For every nonbaseline treatment
js1, the MTC analysis gives us the log odds ratio:0
@ d1;2«
d1;m
1
A|N
0
@
0
@ n2«
nm
1
A;S
1
A;which can be used to obtain the distribution of the nonbase-
line treatments’ log odds conditional on q1:0
@ q2«
qm
1
Aq1|N
0
@
0
@ q1þ n2«
q1 þ nm
1
A;S
1
A:Then, for any treatment i the risk ispi5 logit
1ðqiÞ;as discussed in Section 3. The pi are the measurements used
in the SMAA analysis (thus xik5pi, where pi is obtained for
criterion k). In the SMAA simulation, to obtain samples of
the pi’s, we first sample the baseline log odds q1 and then
sample the log odds qi for all other alternatives based on
q1 and transform them to risk, as given above. Note that
ranking the treatments based on the pi is equivalent to rank-
ing them based on the d1,i (with d1,i5 0) and will thus re-
sult in the same rank probabilities as from the MTC
analysis if the d1,i accurately reflect the posterior distribu-
tion. The rank probabilities in MTC [8] are calculated for
a single criterion and are therefore distinct from the rank
acceptabilities discussed in Section 2, which incorporate
trade-offs between multiple criteria.
Different methods can be used to arrive at a sensible
assumption for the baseline log odds q1. One could use
an observational effectiveness study with a suitable popula-
tion, let a clinical expert provide estimates, or attempt to
derive them from the included trials. In this article, we will
apply arm-based pooling of the placebo arms. This is
Table 1. The number of studies included in the network meta-analysis
for each criterion
Criterion Placebo Fluoxetine Paroxetine Sertraline Venlafaxine Total
HAM-D 8 18 9 8 9 24
Diarrhea 5 11 7 8 5 17
Dizziness 3 9 4 5 6 12
Headache 5 12 8 8 6 19
Insomnia 7 12 8 6 6 18
Nausea 6 15 9 8 8 22
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of the effects found in the individual studies.
Because the risk scale is bound to [0,1], either vkðxikÞ5xik
or vkðxikÞ51 xik can be used as the partial value function
vk for any dichotomous criterion k, respectively, when more
or less events are preferred (Section 2). We will return to
the advantages and disadvantages of this approach in the
discussion.Total 8 18 10 9 9 25
Abbreviation: HAM-D, Hamilton Rating Scale for Depression.
Fig. 2. Evidence network of studies comparing the four included
second-generation antidepressants and placebo. The width of the
lines indicates the number of studies that include that comparison
(the minimum is 1 and the maximum 6).5. Application to antidepressants
To illustrate the use of MTC/SMAA, we used an exist-
ing systematic review [9] to create a model for evaluating
the comparative BR profiles of four second-generation an-
tidepressants (fluoxetine, paroxetine, sertraline, and venla-
faxine) and placebo. The application is meant as an
example, and the results should be interpreted with care.
A full BR analysis of antidepressants should ideally be
based on a more recent systematic review that explicitly in-
cludes placebo-controlled studies. This is even more im-
portant in the light of recent doubt on the efficacy of
antidepressants [16]. Even if we consider the efficacy of
antidepressants to be proven, in the context of a multicrite-
ria decision model, consideration of other factors may im-
ply that placebo is the best option because the placebo
response in depression trials is considerable [17].
5.1. Previous work
The review included 46 studies comparing 10 second-
generation antidepressants on the Hamilton Rating Scale
for Depression (HAM-D) or Montgomery-Asberg Depres-
sion Rating Scale (MADRS). In total, 20 comparisons were
made in the included studies (of 45 possible comparisons).
Meta-analysis was applied for just three comparisons using
16 studies in total. All meta-analyses assessed efficacy
(50% or greater improvement from baseline on the
HAM-D or MADRS scale) relative to fluoxetine, and stud-
ies between the other drugs (paroxetine, sertraline, and
venlafaxine) were not considered. Meta-analysis yielded
risk ratios relative to fluoxetine, with a significant but small
additional effect for sertraline and venlafaxine. The authors
concluded that the four antidepressants did not differ
substantially for treatment of major depressive disorder.
A more recent review [18] used an MTC analysis to show
that there are differences among second-generation antide-
pressants in terms of efficacy and the proportion of patients
completing the study.
5.2. Methods
An MTC/SMAA analysis was performed to compare flu-
oxetine, paroxetine, sertraline, venlafaxine, and placebo on
one benefit criterion (efficacy) and five risk criteria. Effi-
cacy was assessed by means of treatment response, defined
as a 50% or greater improvement on the HAM-D ratingscale for depression. The five risk criteria corresponded to
the most common adverse drug reactions (ADRs): diarrhea,
dizziness, headache, insomnia, and nausea. All the criteria
were measured in terms of absolute risk, based on dichoto-
mous data from the included trials.
As the study by Hansen et al. [9] did not include sufficient
information to construct the MTC models, we did not take
the measurements directly from the review but used the in-
cluded individual studies to perform our own analysis. Al-
though the review did not consider placebo, sufficient
studies with a placebo arm were present to include it in the
analysis. The articles included in the review were retrieved
and the data extracted. We used the GeMTC software
(http://drugis.org/gemtc) [19] to generate MTC models for
the 25 studies (Table 1 and Fig. 2) comparing fluoxetine, pa-
roxetine, sertraline, venlafaxine, and placebo. We used the
homogeneous variance assumption and specified a uniform
prior s | u(0,4) for the random effects variance. For the trial
baseline effects mi and random effects di,b(i),y, we specified
a Nð0; 103Þ prior. Markov Chain Monte Carlo simulation
with four parallel chains of 30,000 tuning and 20,000 simu-
lation iterations each was used to estimate each MTCmodel,
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(R Foundation, Vienna, Austria) [20]. Inconsistency was
primarily assessed using node-splitting models [12], and
inconsistency models [11] were run as a secondary analysis.
Convergence was assessed using the Brooks-Gelman-Rubin
diagnostic [21], where a potential scale reduction factor of
1.05 or lower was considered sufficient if visual inspection
of the convergence plots and time series also indicated
convergence.
We constructed an SMAA model with the measure-
ments derived from the consistency models and baseline
estimates derived from the trials and discussed with an ex-
pert. The SMAA model was computed using R with 10,000
Monte Carlo iterations giving sufficient accuracy for the
indices [22]. The SMAA analyses were performed for three
scenarios: one with missing preference information and
two with a criteria ranking elicited from the expert: mild
and severe depression. The data files are available online
at http://drugis.org/network-br. There we also provide
a model for the JSMAA software (Tommi Tervonen,
Rotterdam, The Netherlands) [23] that allows the reader
to explore the trade-offs in an interactive graphical user
interface.Odds ratio compared with placebo
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Fig. 3. Network meta-analysis results: odds ratios relative to placebo, with
incidence for the active treatment. CrI, credibility interval.5.3. Results
5.3.1. Inconsistency analysis
The node-splitting analysis of inconsistency revealed two
potential problems at the a5 0.05 significance level,
although given that there were 56 comparisons, it is to be ex-
pected that some are significant because of chance. However,
we chose not to correct the threshold a priori but rather to in-
vestigate these two cases. One occurred in the headache net-
work, where one split node was significant, and the other in
the nausea network, where two directly related split nodes
were significant. In neither of these cases could we identify
any systematic differences between the studies, and as the
number of significant findings is compatible with chance,
we decided to continue on the basis of consistencymodels in-
cluding all studies. The studies involved in these compari-
sons did not lead to inconsistencies in the other evaluated
networks, and the secondary analysis using inconsistency
models did not indicate any inconsistencies.5.3.2. Consistency analysis
The results of the consistency analysis are visualized as
forest plots for the odds ratio relative to placebo in Fig. 3.Odds ratio compared with placebo
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CrIs for treatment response than pairwise meta-analysis.
Therefore the evidence from the studies additionally in-
cluded in the MTC model discriminates the drugs better
with respect to efficacy.Fluoxetine Paroxetine Placebo Sertraline Venlafaxine
0.
0
0.
2
0.
4
0 Rank.3
Rank.4
Rank.5
Fig. 4. Rank acceptabilities for the preference-free model.5.3.3. Preference-free model
Baseline estimates were derived by random effects pool-
ing of the placebo arms (Table 2) and discussed with an ex-
pert, who compared them with sources known to him and
did not contest the values or the method used to derive
them. He did note that these values are expected to vary
greatly between trials and that this fact is reflected in the
width of the confidence intervals.
The rank acceptabilities with missing preferences are
shown in Fig. 4. There is a large share of the possible pref-
erences for which placebo attains rank 1. From the central
weights (Fig. 5), it is estimated that the preference scenar-
ios that are favorable to placebo have a low weight for
efficacy and that a ‘‘typical’’ DM that would choose pla-
cebo implicitly finds each of the ADRs to be about twice
as important as efficacy. Placebo is also the only alternative
to attain a confidence factor close to 1 (Table 3).
Fluoxetine has a low confidence factor (0.12) for its cen-
tral weights, and in fact given its central weights, other
alternatives have a higher first-rank acceptability. Thus, flu-
oxetine is likely to be dominated by the other alternatives.
In general, if efficacy is highly valued, placebo is unlikely
to be the best option, but it is difficult to choose a drug
based on the data.0
0.
355.3.4. Mild depression
Preferences for the mild depression scenario were eli-
cited from the expert using ordinal swing weighting. This
resulted in the following ranking of the criteria: insom-
niaOHAM-DO dizzinessO nauseaO diarrheaO head-
ache. The rank acceptabilities for this scenario are shown in
Fig. 6. Placebo obtains the highest first-rank acceptability
(0.56), followed by paroxetine (0.28), whereas venlafaxine
has the highest last-rank acceptability (0.62), followed by
sertraline (0.24). Clearly, the high incidence of bothTable 2. Baseline measurements derived from the placebo trials, given
as mean6 standard error for the log-odds, and the corresponding
median and 95% CrI of the resulting logit normal distribution for
the absolute risk
Criterion Parameters Risk (95% CrI)
HAM-D 0.176 0.11 0.46 (0.40, 0.51)
Diarrhea 2.196 0.21 0.10 (0.07, 0.14)
Dizziness 2.236 0.61 0.10 (0.03, 0.26)
Headache 1.206 0.29 0.23 (0.15, 0.35)
Insomnia 2.616 0.19 0.07 (0.05, 0.10)
Nausea 2.026 0.19 0.11 (0.08, 0.16)
Abbreviations: CrI, credibility interval; HAM-D, Hamilton Rating
Scale for Depression.insomnia and dizziness is unfavorable to venlafaxine given
the preferences. Only placebo, fluoxetine, and paroxetine
have O0.5 probability of being among the best three, and
only placebo and paroxetine have!0.5 probability of be-
ing among the worst three.5.3.5. Severe depression
The preferences elicited for this scenario differed only
in that the insomnia and HAM-D criteria were swapped.
The rank acceptabilities for severe depression are shown
in Fig. 7. As would be expected based on the central
weights analysis with missing preferences, ranking
HAM-D as the most important criterion reverses the situa-
tion for placebo, which now has only 0.09 first-rank accept-
ability and 0.56 last-rank acceptability. Placebo is also the
only alternative to have !0.5 probability of being among
the best three. Paroxetine has the highest first-rank accept-
ability (0.47), and paroxetine and sertraline are the only
alternatives that have !0.5 probability of being among
the worst three.Criterion
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Fig. 5. Central weights for the preference-free model.
Table 3. Central weights and CFs for the preference-free model
Alternative CF HAM-D Diarrhea Dizziness Headache Insomnia Nausea
Fluoxetine 0.12 0.21 0.09 0.28 0.12 0.09 0.20
Paroxetine 0.57 0.30 0.18 0.12 0.12 0.14 0.14
Placebo 0.99 0.09 0.18 0.18 0.16 0.20 0.20
Sertraline 0.55 0.28 0.08 0.30 0.13 0.10 0.12
Venlafaxine 0.63 0.29 0.18 0.08 0.25 0.12 0.09
Abbreviations: CF, confidence factor; HAM-D, Hamilton Rating Scale for Depression
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Pharmacological decision making is a complex domain
in which decisions regarding multiple criteria are informed
by complex evidence networks consisting of heteroge-
neous clinical studies. This article introduced MTC/
SMAA, which uses the MTC evidence synthesis method
together with SMAA to assess multicriteria BR trade-offs
while taking into account all available evidence from clin-
ical trials.
The MTC/SMAA method has four main advantages.
First, MTC/SMAA allows taking into account all the avail-
able evidence no matter whether the treatments are directly
or indirectly related. Second, a group of treatments without
a common comparator can be analyzed, which is impossi-
ble with pairwise evidence synthesis methods. Third, incon-
sistencies in the evidence structure because of incompatible
study design can be detected early in the analysis and sys-
tematically removed if the inconsistency is judged to be
clinically relevant. Fourth, application of SMAA enables
explicit assessment of trade-offs that exist between the cri-
teria and provides valuable insights even if the DMs are not
willing or able to provide exact preferences.6.1. Case study
We illustrated the MTC/SMAA method with a case
study on second-generation antidepressants. Although the
case study is indicative of the method’s feasibility, further
work should evaluate the model in other therapeutic groups.Fluoxetine Paroxetine Placebo Sertraline Venlafaxine
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Rank.1
Rank.2
Rank.3
Rank.4
Rank.5
Fig. 6. Rank acceptabilities for the mild depression scenario.As we demonstrated in the example, a preference-free
analysis of the central weight vectors can provide substan-
tial insight into trade-offs between the treatments under
consideration. As such, an SMAA central weights analysis
of the most important outcomes could be a valuable addi-
tion to any (network) meta-analysis. It allows drawing firm-
er conclusions on which treatments are likely to be most
suited to specific situations and which treatments are un-
likely to be the best in any situation. The mild and severe
preference scenarios showed that for severe depression,
treatment with an antidepressant is warranted, but for mild
depression this is not clear. Recent research suggests that
placebo may be effective even without deception [24] (in
irritable bowel syndrome), so it may be worthwhile to ex-
plore this option for mildly depressed patients. The analy-
ses also suggest that fluoxetine is unlikely to be the best
among the five alternatives.
However, the data do not conclusively distinguish the al-
ternatives, especially the active treatments, and given the
amount of data it is likely that much of this uncertainty is
inherent to the field, especially when distinguishing the ac-
tive treatment options. Some improvement may be possible
by eliciting more precise weights. However, except for pla-
cebo in the mild depression scenario, making the weights
more precise within the constraints imposed by the ordinal
preferences elicited from the expert would not allow much
more conclusive results because the data have a high degree
of uncertainty.
Compared with the systematic review on which we
based the case study, the MTC/SMAA analysis explicitlyFluoxetine Paroxetine Placebo Sertraline Venlafaxine
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Fig. 7. Rank acceptabilities for the severe depression scenario.
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gives a clearer picture of the strengths and weaknesses of
the alternatives. Including placebo in the analysis provides
further insight into the trade-offs. Moreover, the model can
quantitatively support the statement, also made in the orig-
inal review, that it is difficult to choose among the four con-
sidered antidepressants.6.2. Limitations and future work
The main challenges in applying MTC/SMAA are the
evaluation of inconsistency and estimation of baseline
effects. Assessing inconsistency is especially difficult in
cases where many potential inconsistencies have to be con-
sidered (large evidence networks or many different criteria)
because significant results may also arise by chance. Differ-
ent methods to assess inconsistency have been proposed
[6,11,12], and general consensus on the best method has
not yet been reached. The second concern is the scale used
for the criteria measurements. We developed a procedure
for converting the relative scales from evidence synthesis
to absolute ones to be used in decision making using min-
imal information. However, baseline effects have to be es-
timated, and further work is necessary to identify the best
way to do this.
Another consideration is the scale on which criteria are
evaluated in preference elicitation. In contrast to the previ-
ous work on SMAA for BR analysis [4], we choose to use
the full [0,1] scale instead of the hull of the 95% confidence
intervals. This has the advantage that trade-offs are easier to
evaluate and that introducing additional alternatives does
not require re-eliciting the preferences. The disadvantage
of this approach is that a stronger linearity assumption on
the partial value functions is required (see the study by
Tervonen et al. [4]). This limitation is especially important
when the observed frequencies differ greatly, for example,
when a trade-off between high efficacy and rare but serious
adverse events needs to be made. In those cases, the scales
should be assessed using the confidence interval hull. Of
course, for scales that do not have natural bounds (e.g.,
weight gain in kilograms) the confidence interval hull ap-
proach is the only viable option.
In the present work, we applied an SMAA decision
model based on additive value functions. Although the
additive model is widely applied and reasonably easy to un-
derstand, we acknowledge that other approaches are possi-
ble. For example, DEA (data envelopment analysis) models
have been commonly applied in costebenefit analyses out-
side the area of health care, and there is also a SMAA var-
iant for DEA [25]. Future work should assess whether other
simulation-based decision models are applicable in the con-
text of drug BR analysis.
Finally, our model is based only on criteria that are mea-
sured in clinical trials, which is appropriate in the context
of health policy decision making. However, other criteria
may need to be considered, such as cost in reimbursementdecisions or the route of administration in prescription
decisions. Although we did not consider such criteria, they
would not be difficult to include in an MTC/SMAA
analysis.Acknowledgments
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